Trial · NCT03399786
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) | Placebo IV Q4W | 1.9 | Standard Error 6.5 | Percent Change | |
| Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) | Evinacumab 15 mg/kg IV Q4W | -47.1 | Standard Error 4.6 | Percent Change | |
| Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 24 (ITT Estimand) | Placebo IV Q4W | -4.5 | Standard Error 4.8 | Percent Change | |
| Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 24 (ITT Estimand) | Evinacumab 15 mg/kg IV Q4W | -41.4 | Standard Error 3.3 | Percent Change | |
| Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 24 (ITT Estimand) | Placebo IV Q4W | 2.0 | Standard Error 5.4 | Percent Change | |
| Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 24 (ITT Estimand) | Evinacumab 15 mg/kg IV Q4W | -49.7 | Standard Error 3.8 | Percent Change | |
| Percent Change in Total Cholesterol (TC) From Baseline to Week 24 (ITT Estimand) | Placebo IV Q4W | 1.0 | Standard Error 4.2 | Percent Change | |
| Percent Change in Total Cholesterol (TC) From Baseline to Week 24 (ITT Estimand) | Evinacumab 15 mg/kg IV Q4W | -47.4 | Standard Error 3.0 | Percent Change | |
| Percentage of Participants With ≥30% Reduction in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (ITT Estimand) | Placebo IV Q4W | 18.2 | Percentage of Participants | ||
| Percentage of Participants With ≥30% Reduction in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (ITT Estimand) | Evinacumab 15 mg/kg IV Q4W | 83.7 | Percentage of Participants | ||
| Percentage of Participants With ≥50% Reduction in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (ITT Estimand) | Placebo IV Q4W | 4.5 | Percentage of Participants | ||
| Percentage of Participants With ≥50% Reduction in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (ITT Estimand) | Evinacumab 15 mg/kg IV Q4W | 55.8 | Percentage of Participants | ||
| Absolute Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (ITT Estimand) | Placebo IV Q4W | -2.6 | Standard Error 17.6 | Milligrams per Deciliter (mg/dL) | |
| Absolute Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (ITT Estimand) | Evinacumab 15 mg/kg IV Q4W | -134.7 | Standard Error 12.4 | Milligrams per Deciliter (mg/dL) | |
| Percentage of Participants Who Met United States (US) Apheresis Eligibility Criteria at Week 24 (ITT Estimand) | Placebo IV Q4W | 22.7 | Percentage of Participants | ||
| Percentage of Participants Who Met United States (US) Apheresis Eligibility Criteria at Week 24 (ITT Estimand) | Evinacumab 15 mg/kg IV Q4W | 7.0 | Percentage of Participants | ||
| Percentage of Participants With Low-Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter (mg/dL) (2.59 Millimoles Per Liter [mmol/L]) at Week 24 (ITT Estimand) | Placebo IV Q4W | 22.7 | Percentage of Participants | ||
| Percentage of Participants With Low-Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter (mg/dL) (2.59 Millimoles Per Liter [mmol/L]) at Week 24 (ITT Estimand) | Evinacumab 15 mg/kg IV Q4W | 46.5 | Percentage of Participants | ||
| Percentage of Participants Who Met European Union (EU) Apheresis Eligibility Criteria at Week 24 (ITT Estimand) | Placebo IV Q4W | 77.3 | Percentage of Participants | ||
| Percentage of Participants Who Met European Union (EU) Apheresis Eligibility Criteria at Week 24 (ITT Estimand) | Evinacumab 15 mg/kg IV Q4W | 32.6 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03399786/results